Biotech on the Brink of Breaking Out

HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Below are some healthcare plays starting to gain investor interest that could breakout at any time. Do your research now.

One of the best examples of the opportunity investors have in front of them is BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, is developing a therapy "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue. The company traded above $3 dollars last year before hitting lows with the rest of the biotech industry. The company has started to rally in lockstep with the industry's ETF: IBB, and could be on the verge of a breakout that may send BRTX above their 2018 highs. Get a jumpstart on the crowd by researching BRTX today.

Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), Fortress Biotech, Inc. (FBIO), BioLineRx Ltd. (BLRX), Can-Fite BioPharma Ltd. (CANF) and GW Pharmaceuticals, Inc. (GWPH).

According to Grand View Research, the global obesity treatment market was valued at $3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight. These are just a couple making companies developing weight management solutions so valuable to investors.

One of the more novel approaches to fighting this obesity epidemic is being developed by BioRestorative Therapies, Inc. (BRTX) (Market Cap: $9.458M, Share Price: $0.74), a life sciences company focused on stem cell-based therapies, developing a therapy "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.

BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan.

Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.

____

Fortress Biotech, Inc. (FBIO) (Market Cap: $126.395M, Share Price: $2.23) announced that Caelum Biosciences Inc, founded by Fortress, has signed a strategic agreement with Alexion Pharmaceuticals Inc to advance the development of CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis.

____

BioLineRx Ltd. (BLRX) (Market Cap: $89.162M, Share Price: $0.7341) a clinical-stage biopharmaceutical company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead oncology candidate, BL-8040, for the treatment of pancreatic cancer.

____

Can-Fite BioPharma Ltd. (CANF) (Market Cap: $27.448M Share Price: $1.20), a biotechnology company working to advance a pipeline of small molecular drugs that address cancer, live and inflammatory diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled, ''Use of A3 adenosine receptor agonist in the treatment of Osteoarthritis."

____

GW Pharmaceuticals plc (GWPH) (Market Cap: $4.75B, Share Price: $146.86), a biopharmaceutical company focused on discovering, developing and commercializing treatment options from its proprietary cannabinoid platform, recently presented at the JP Morgan healthcare conference.

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $25,000 cash for February services and expects to be compensated an additional $25,000 for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.